Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study
Tuesday, July 1, 2014
New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World
Vaccine efficacy was evaluated by immunizing volunteer participants with an oral dose of the PXVX0200 vaccine or placebo and then subsequently exposing them to the cholera-causing agent (Vibrio cholerae O1 El Tor). Volunteer participants in this challenge study were divided into two groups – the first group was vaccinated and then challenged at 10 days after vaccination, and a second, separate group of volunteer participants was challenged at 90 days post vaccination to further evaluate duration of vaccine protection. Read more.